Curative drug for genetic diseases due to nonsense mutation to be transfered by a French Technology Transfer Office

Center name Тестовый центр
Summary A French Technology Transfer Office (TTO) offers an new treatment dealing with the primary cause of genetic diseases due to nonsense mutation. It turns the protein with such a mutation into a complete functional protein, which allows to consider a full recovery. The French TTO is looking for pharmaceutical corporates or biotech companies interested by a licensing or a technical cooperation agreement. Investors operating in biotechnology are also targeted in the context of a financial agreement.
Description of the offer A Technology Transfer Office (TTO) is acting on behalf some major life sciences research labs operating in the Paris region. One of them has demonstrated the mechanism of action of a new orally-administered molecule as a curative treatment for genetic disorders due to nonsense mutations. The proof of concept has been performed on cystic fibrosis, and is under investigation for other nonsense mutations. *Definitions : - The Messenger Ribonucleic Acid (mRNA) is a temporary and unfinished copy of the Desoxyribonucleic Acid (DNA) which lies in nucleus cells and contains all genetic properties of a whole living subject, - the ribosom is the cell part which transcripts the mRNA and produces a full-length protein according to the transcripted information, - a nonsense mutation is the resulting point from a failing DNA where genetic information is missing and so-replaced by a premature stop signal in the mRNA. *Market challenges : Nonsense mutations are responsible for 10% of all genetic diseases, mainly for cystic fibrosis whose symptoms are acute respiratory failure and digestive capacity impairment. The number of patients with this severe chronic disease is about 30,000 in United States and 40,000 in Europe (7,000 in France). Until now, there is no curative treatment but only symptomatic relief procedures which needs a strong coordination between several medical specialties such as physiotherapy, nutrition and clinical psychology. * State of the art : Among all genetic diseases due to nonsense mutation, Duchenne Muscular Dystrophy (DMD) is the only one to benefit from an existing curative treatment using ataluren drug. Nevertheless, clinical investigation using ataluren hasn't shown any significant impact on other nonsense mutation diseases. Indeed, the biological target of ataluren is not known, and its mechanism of action is uncertain : it is thought to make ribosomes less sensitive to premature stop signals but it hasn't been proved until now. * Proposed technology : A new ingredient has been extracted from a specific fungus, and used as the active principle of an innovative drug. Applied to cystic fibrosis, it has been proved to enable the ribosom to correctly transcript the mRNA without any disruption due to nonsense mutation. Doing so, it allows the production of a full-length and functional protein. The French TTO is looking for pharmaceutical corporates, biotech companies and startups interested by a licensing agreement. A technical cooperation agreement is also open to be discussed in case of further investigation on cystic fibrosis or other genetic disesases due to nonsense mutation. Investors operating in biotechnology are also sought in case they are interested in a startup creation. *Keywords : genetic disorder, nonsense mutation, exon skipping, cystic fibrosis.
Advantages and Innovations The innovative drug enables the ribosom to correctly transcript the mRNA without any disruption due to nonsense mutation. Doing so, it can be used as a treatment for genetic diseases due to nonsense mutation such as cystic fibrosis. *Advantages : - Compared to ataluren, the new drug is 2.5 times more efficient when used as an indication for cystic fibrosis, leading to a 80% production ratio of full-length and functional proteins (see figure), - the new drug delivery process is much patient-friendly as compared to ataluren (oral pill versus needle injection), - the active principle is easily available, since the fungus extract as well as the molecule have been clearly identified, - the mechanism of action could be transfered to other genetic diseases due to nonsense mutation.
Current Stage of Development In cellulo Proof of Concept (POC) has been performed and validated. In vivo POC on animal model is in progress for cystic fibrosis. In cellulo and in vivo POC is under investigation for another genetic disease different from Duchenne Muscular Dystrophy (DMD), due to nonsense mutation.
Technological Keywords 06001015 Pharmaceutical Products / Drugs
06002004 Protein Engineering
06002007 In vitro Testing, Trials
06002009 Molecular design
Market Keywords 04006 Cellular and Molecular Biology
04015 Gene Expression, Proteome Research
05003001 Therapeutic services
05003005 Drug delivery and other equipment
Copyright Patent(s) applied for but not yet granted
Comments Regarding IPR Status Priority patent application filed in 2016.
Type of Partnership Required License Agreement
Financial Agreement
Technical cooperation agreement
Type and Role of Partner Sought The partner sought could be a pharmaceutical corporate, biotech company or startup operating in the drug design for genetic diseases due to nonsense mutation (cystic fibrosis or others), which may be interested by a licence agreement. These companies may also be interested by a technical cooperation agreement in case of further development or co-development, such as in vivo trials dealing with other genetic disease different from cystic fibrosis. Moreover, investors operating in biotechnology could be interested by a financial agreement in the context of creating a new startup company.
Date of creation 26.04.2018
Profile type Technology offer
Profile openness to interact N
Profile from EEN Y

Dear foreign Participant of external economic activity

Welcome to Russian consortium of Enterprise Europe Network website!

Этот сайт использует «cookies» и собирает следующие данные в целях улучшения его работы (Yandex Metrika, Google Analytics) : IP-адрес компьютера, страна, дата и время посещения, тип браузера, тип операционной системы, модель мобильного устройства, тип устроиства. Для продолжения работы с сайтом нажмите: «Согласен(на)»